製品番号: HY-14805A

Tecovirimat monohydrate

(別名: ST-246 monohydrate)

3 Cited Publications

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Tecovirimat (ST-246) monohydrate is the monohydrate form of Tecovirimat (HY-14805). Tecovirimat monohydrate is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat monohydrate is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat monohydrate targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat monohydrate exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat monohydrate could be used in the study for orthopoxvirus-induced diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 97.35%
CAS 番号: 1162664-19-8
分子式: C₁₉H₁₇F₃N₂O₄
分子量:394.34

保管条件:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Tecovirimat monohydrate 構造式

CAS 番号: 1162664-19-8

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Tecovirimat monohydrate (0-50 μM, 3 days) is a potent and specific inhibitor of orthopoxvirus replication that is active against a broad spectrum of orthopoxviruses^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

Vero cells
Concentration:

0-50 μM
Incubation Time:

3 days
Result:

Was more potent relative to Cidofovir (CDV) (HY-17438) after vaccinia virus strain NYCBH infection in cytopathic effect (CPE)-based assays in vero cells.

体内実験

Tecovirimat monohydrate (50 mg/kg, oral gavage, twice a day for 14 days) mounts a protective immune response to vaccinia virus infection in a lethal intranasal vaccinia virus challenge model of mice^[1].
Tecovirimat monohydrate (50 mg/kg, oral gavage, 5 days) can inhibit vaccinia virus-induced lesion formation following i.v. viral inoculation in Vaccinia virus-mouse tail lesion model^[1].
Tecovirimat monohydrate (100 mg/kg, p.o., daily for various durations of 5, 7, 10, or 14 days) significantly decreases in mortality of cowpox virus (CV)-infected mice^[2].

Pharmacokinetic parameters of ST-246 in mice^[1]

Dosage (mg/kg)	T_max (h)	C_max (μg/mL)	AUC_0-t (μg·h/mL)	T_1/2 (h)
30	2.7	32.5	284.2	2.5
100	1.0	62.2	287.6	2.5

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Weanling BALB/c mice challenged with vaccinia virus strain(4 to 6 weeks of age and weighing 15 to 20 g)^[1]
Dosage:

50 mg/kg
Administration:

oral gavage, twice a day for 14 days
Result:

Tecovirimat monohydrate-treated mice mounted a protective immune response to vaccinia virus infection in a lethal intranasal vaccinia virus challenge model.

Animal Model:

NMRI mice inoculated via the tail vein with vaccinia virus(4 to 6 weeks of age and weighing 15 to 20 g)^[1]
Dosage:

50 mg/kg
Administration:

oral gavage, 5 days
Result:

Showed a dose-dependent reduction in the numbers of tail lesions at day 8 postinfection relative to placebo-treated control animals in mice.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 1162664-19-8
性状 Solid
分子量 394.34
分子式 C₁₉H₁₇F₃N₂O₄
Color White to off-white
SMILES

O=C(NN(C([C@]1([H])[C@@]2([H])[C@@](C3)([H])[C@@]3([H])[C@@](C=C2)([H])[C@]41[H])=O)C4=O)C5=CC=C(C(F)(F)F)C=C5.O
別名

ST-246 monohydrate
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All Microbiological Assay

Sort by:

Journal Impact Factor

BMC Microbiol

Pathogenic signatures and therapeutic evaluation of emergent MPXV Clade Ib in low-susceptibility and immunocompromised mouse models. [Abstract]

2026 Jun 9. PMID: 42260341
Antiviral Res

Salinomycin inhibits orthopoxvirus infection in vitro and in vivo by blocking endosomal acidification. [Abstract]

2026 May:249:106403. PMID: 41941992
Biosaf Health

2025 Jan 5.

Tecovirimat monohydrate purchased from MedChemExpress. Usage Cited in: Biosaf Health. 2025 Jan 5.

Inhibition of EEV by ST-246 (Tecovirimat). HeLa cells were infected with VACV WR at a MOI of 3 for 2 h and then added increased dosages of ST-246 for another 22 h. The EEV was collected and titrated by BSC-1 cells.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (253.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5359 mL

12.6794 mL

25.3588 mL

5 mM

0.5072 mL

2.5359 mL

5.0718 mL

10 mM

0.2536 mL

1.2679 mL

2.5359 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Quenelle DC, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice[J]. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. [Content Brief]

[2]. DeLaurentis CE, et al. New Perspectives on Antimicrobial Agents: Tecovirimat monohydrate for Treatment of Human Monkeypox Virus[J]. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0122622. [Content Brief]

[3]. Yang G, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge[J]. J Virol. 2005 Oct;79(20):13139-49. [Content Brief]

[4]. Russo AT, et al. An overview of Tecovirimat monohydrate for smallpox treatment and expanded anti-orthopoxvirus applications[J]. Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344. [Content Brief]

[5]. TYAVANAGIMATT SR, et al., Rehydration of micronized tecovirimat monohydrate. WO2015077143.

[6]. Almehmadi M, et al. A Glance at the Development and Patent Literature of Tecovirimat monohydrate: The First-in-Class Therapy for Emerging Monkeypox Outbreak[J]. Viruses. 2022 Aug 25;14(9):1870. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5359 mL	12.6794 mL	25.3588 mL	63.3971 mL
	5 mM	0.5072 mL	2.5359 mL	5.0718 mL	12.6794 mL
	10 mM	0.2536 mL	1.2679 mL	2.5359 mL	6.3397 mL
	15 mM	0.1691 mL	0.8453 mL	1.6906 mL	4.2265 mL
	20 mM	0.1268 mL	0.6340 mL	1.2679 mL	3.1699 mL
	25 mM	0.1014 mL	0.5072 mL	1.0144 mL	2.5359 mL
	30 mM	0.0845 mL	0.4226 mL	0.8453 mL	2.1132 mL
	40 mM	0.0634 mL	0.3170 mL	0.6340 mL	1.5849 mL
	50 mM	0.0507 mL	0.2536 mL	0.5072 mL	1.2679 mL
	60 mM	0.0423 mL	0.2113 mL	0.4226 mL	1.0566 mL
	80 mM	0.0317 mL	0.1585 mL	0.3170 mL	0.7925 mL
	100 mM	0.0254 mL	0.1268 mL	0.2536 mL	0.6340 mL

Keywords

Tecovirimat monohydrate

3 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Tecovirimat monohydrate

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Anti-Orthopoxvirus Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Tecovirimat monohydrate

生物活性

化学情報

Publications (3)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Tecovirimat monohydrate

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Anti-Orthopoxvirus Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Tecovirimat monohydrate

生物活性

化学情報

Publications (3)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Tecovirimat monohydrate 関連分類

HY-14805A 関連分類